V.l.n.r.: Prof. Wehrspohn (Fraunhofer-Vorstand), Dr. Schlumberger (Vorstandsvorsitzender EUROIMMUN AG), Prof. Charli Kruse (Einrichtungsleiter Fraunhofer-EMB)
Processing of cell cultures
Testkit ©EUROIMMUN Medizinische Labordiagnostika AG

The Fraunhofer EMB in Lübeck is supporting EUROIMMUN AG in producing larger quantities of its new serological test systems for the diagnosis of COVID-19. EUROIMMUN is one of the first companies in Europe to offer a test for the determination of antibodies against SARS-CoV-2 in serum samples, which enables the identification of persons who have already had contact with the virus. This is important to find out who has already been through the infection. In addition, there is evidence that these tests detect those antibodies that are able to neutralize the virus and thus provide immunity to SARS-CoV-2.

One of the two major areas of research at the Fraunhofer Research Institute for Marine Biotechnology and Cell Technology is the development and exploitation of cell-based technologies. A major focus here is the industrial reproduction of cell cultures growing adherently, i.e. on surfaces, outside the body. Due to the good contacts within the life science industry in Lübeck, both partners were able to come to a contractual cooperation within one week. With its existing laboratory infrastructure and expertise, the EMB supports EUROIMMUN AG in producing the antigen required for the test systems in large quantities and thus provides an essential starting material for the production of the test kits.


Read the press reports here:


Link to the Fraunhofer Press Release oder Report from the Lübecker Nachrichten